Gangliosides During Tumor Progression in Patients With Prostate Cancer
Abstract
The project objectives are 1 to identify the gangliosides Gs of Prostate cancer (CaP) that are immunogenic so that they can be used as targets to develop immunotherapy for prostate cancer; 2 to determine the total and specific Cap-Gs released into the blood and 3 to assess the nature of immunosuppression induced by CaP-Cs. Last year, we have found out that the neoplastic transformation of prostate epithelial cells involve Cs with Cal-CalNAc-Cal-Glucosylceramide backbone by comparing the normal prostatic epithelial with five prostate cancer cell lines, namely PC-3, DUl45, LNCaP-FCC-lO, LNCaP-FCC and HH87O. This year, we have made novel and unique observations relevant to early diagnosis of the localized disease, which include 1 Identifying GMlb, GD1a, GalNAc-GM1b and GalNAc-GD1a as unique Cs of CaP. 2 IgM antibodies in the sera of CaP patients with localized disease (T1b/c) reacted strongly to GM1b in thin layer chromatography (TLC). 3 Patients with localized disease had high titers of GD1a. 4 A study of the total serum Cs profile was completed for all stages. 5 Using endogenous immune response, we identify that the Cs GMlb and GD1a are released into circulation. 6 The Cs GM2 and GMlb observed in CaP cell lines may be artifacts of tissue culture conditions, which are known to augment the expression of GalNAc-transferase. The endogenous immune response to GMlb and GD1a make the anti-GsIgM as potential markers of early diagnosis of localized prostate cancer. Ultimately these findings will enable formulating an allergenic CaP vaccine.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2003
- Accession Number
- ADA418202
Entities
People
- Mepur H. Ravindranath